Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4884 · 1 trial · 1 indication
DLT is defined as the occurrence of protocol-specified toxicities, unless clearly related to disease progression or intercurrent illness.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with experience an AE will be reported.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-4884 Dose Escalation Schedule A | EXPERIMENTAL | Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met. |
| MK-4884 Dose Escalation Schedule B | EXPERIMENTAL | Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met. |
| Name | Type | Description |
|---|---|---|
| MK-4884 | DRUG | Oral Administration |
Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and/or advanced (metastatic) solid tumors: * Colorectal carcinoma (CRC) * Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoi...
MK-4884 is an investigational small molecule being developed for the treatment of malignant neoplasms, specifically advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MK-4884 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
MK-4884 is currently in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The ongoing Phase 1 trial is actively recruiting participants to evaluate the drug in patients with advanced or metastatic solid tumors.
MK-4884 is being studied in a Phase 1 clinical trial with the identifier NCT07600749. This trial, titled "Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)," is currently recruiting participants and aims to enroll approximately 120 patients.
The MK-4884-001 trial (NCT07600749) is a Phase 1, controlled, open-label study evaluating MK-4884 in adults with advanced or metastatic solid tumors. The trial is recruiting participants in the United States, Canada, Israel, Japan, and Switzerland, with a target enrollment of 120 patients.